Table I.
Baseline characteristics of all patients who received PD with or without PVR.
| Before PSM | After PSM | |||||
|---|---|---|---|---|---|---|
| Index | PVR group (n=138) | Non-PVR group (n=239) | P-value | PVR group (n=123) | Non-PVR group (n=123) | P-value |
| Male, n (%) | 78 (56.5) | 153 (64.0) | 0.150 | 69 (56.1) | 82 (66.7) | 0.089 |
| Age, years | 62.75±8.22 | 61.54±9.01 | 0.197 | 62.70±8.53 | 61.95±10.22 | 0.534 |
| BMI, kg/m2 | 21.70±2.91 | 22.41±2.56 | 0.015 | 21.80±2.95 | 21.80±2.53 | 0.996 |
| Leukocyte, 109/l | 5.82±1.67 | 5.82±1.84 | 0.966 | 5.91±1.68 | 5.95±1.86 | 0.861 |
| ALT, U/l | 35.50 (18.00–79.25) | 45.00 (21.00–84.00) | 0.904 | 39.00 (19.00–82.00) | 51.00 (21.00–115.00) | 0.302 |
| TBIL, µmol/l | 13.00 (8.00–31.13) | 13.70 (7.60–38.60) | 0.660 | 13.00 (8.00–31.00) | 21.70 (10.60–43.80) | 0.226 |
| ALB, g/l | 39.24±4.56 | 39.62±3.76 | 0.383 | 39.20±4.56 | 39.12±3.84 | 0.892 |
| CA125, U/ml | 14.50 (10.00–40.00) | 18.00 (12.00–26.00) | 0.010 | 14.00 (10.00–38.00) | 17.00 (12.00–31.00) | 0.413 |
| CA19-9, U/ml | 120.00 (36.75–642.25) | 86.00 (40.00–218.00) | 0.040 | 115.00 (40.00–642.00) | 100.00 (41.00–438.00) | 0.795 |
| TNM stage, n (%) | ||||||
| Stage I | 30 (21.7) | 106 (44.4) | <0.001 | 30 (24.4) | 33 (26.8) | 0.556 |
| Stage II | 96 (69.6) | 114 (47.7) | 84 (68.3) | 77 (62.6) | ||
| Stage III | 12 (8.7) | 19 (7.9) | 9 (7.3) | 13 (10.6) | ||
| LN metastasis, n (%) | 66 (47.8) | 96 (40.2) | 0.148 | 56 (45.5) | 58 (47.2) | 0.798 |
| Tumor size, cm | 4.06±1.22 | 3.13±1.13 | <0.001 | 3.87±1.08 | 3.71±1.15 | 0.254 |
| R1 resection, n (%) | 5 (3.6) | 14 (5.9) | 0.465 | 5 (4.1) | 7 (5.7) | 0.898 |
| PV invasion, n (%) | 127 (92.0) | – | – | 112 (91.1) | – | – |
| Operating time, min | 485.29±76.52 | 399.95±72.56 | <0.001 | 482.76±76.11 | 433.80±73.37 | <0.001 |
| Intraoperative blood loss, ml | 600.00 (500.00–1000.00) | 460.00 (400.00–600.00) | <0.001 | 600.00 (500.00–900.00) | 460.00 (400.00–800.00) | <0.001 |
| Hospital stay, days | 21.36±9.20 | 19.76±9.67 | 0.314 | 21.80±9.55 | 22.34±9.35 | 0.652 |
PSM, propensity score matched; PD, pancreatoduodenectomy; PVR, portal vein resection; TNM, Tumor-Node-Metastasis; BMI, body mass index; ALT, alanine transaminase; TBIL, total bilirubin; ALB, albumin; CA125, carbohydrate antigen 125; CA19-9, carbohydrate antigen 19-9; LN, lymph node.